Medication-induced hair loss: An update - 15/08/23
Doi : 10.1016/j.jaad.2023.04.022
Lina Alhanshali, BA a, Michael Buontempo, BS b, Jerry Shapiro, MD c, Kristen Lo Sicco, MD c, ⁎ 
a Department of Dermatology, SUNY Downstate College of Medicine, Brooklyn, New York
b Department of Dermatology, Hackensack Meridian School of Medicine, Nutley, New Jersey
c The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York
∗Correspondence to: Kristen Lo Sicco, MD, The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, 12th Floor, New York, NY 10016.The Ronald O. Perelman Department of DermatologyNew York University Grossman School of Medicine240 East 38th Street, 12th FloorNew YorkNY10016
Abstract |
This article discusses drug-induced hair loss, which can occur with many drugs including cytotoxic agents, biologics, and immunomodulating agents, among others. It outlines the diagnosis and management of drug-induced alopecia, with a focus on recently implicated drugs.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, alopecia areata, anagen effluvium, hair loss, medication-induced alopecia, scarring alopecia, telogen effluvium
Plan
| Drs Alhanshali and Buontempo are cofirst authors. |
|
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Disclosures: Dr Shapiro has served on the Advisory Board (Honoraria) for Eli Lilly and Company and as an Investigator (Honoraria) for Pfizer, Inc. Dr Shapiro is a consultant for Aclaris Therapeutics, Incyte, and Replicel Life Sciences. Dr Lo Sicco has served as an Investigator (Grants/Research Funding) and Consultant for Pfizer, Inc. Dr Lo Sicco is a consultant for Aquis. Drs Shapiro and Lo Sicco have been investigators for Regen Lab. Authors Alhanshali and Buontempo have no conflicts to disclose. |
|
| Date of release: August 2023. |
|
| Expiration date: August 2026. |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 2S
P. S20-S28 - août 2023 Retour au numéro
Article précédent
- The role of the scalp biopsy in the evaluation of alopecia
- Leonard C. Sperling
- Janus kinase inhibitors for alopecia areata
- Brett A. King, Brittany G. Craiglow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?